News

"Our translational models give sponsors a high level of confidence when deciding to move a drug candidate into clinical development by providing insights into the pharmacological mechanisms of

By collaborating with University Health Network, the biotechnology company Novera will discover and develop novel therapeutic compounds identified through OICR’s drug discovery program. The company will coordinate the

Under the deal, ImaginAb will be responsible for conducting preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and

The approval comes through Health Canada, the regulating health-care agency of Canada. PharmaRoth CEO Luis Lopez said: "We are very excited that our product is expanding into the

The transaction will enhance Hi-Tech’s leading Sports Nutrition arsenal and expand its distribution through iForce’s strong distribution network. Hi-Tech chairman, president and CEO Jared Wheat said: "The combination

CINRYZE received the designation for investigation in the treatment of antibody mediated rejection (AMR) in patients receiving kidney transplants. The injectable prescription medicine is used to help prevent

Drug Modification Technology (DMT) platform can help address sub-optimal physico-chemical and pharmacokinetic properties of approved drugs and drugs in development. Sphaera’s technology allows for improved delivery of a

The approved medicines include trastuzumab (Herceptin) for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis (a long term

The firm has enrolled the patients using suprachoroidal space (SPS) drug administration in the trial, which is designed to assess CLS-TA to treat macular edema associated with non-infectious